Compare Merck & Co., Inc. (MRK) vs Roundhill Russell 2000 0DTE Covered Call Strat ETF (RDTE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Roundhill Russell 2000 0DTE Covered Call Strat ETF — how do they compare? Merck & Co., Inc. trades at $148.15 (market cap $366.28B), while Roundhill Russell 2000 0DTE Covered Call Strat ETF trades at $27.35. The key difference: Merck & Co., Inc. pays a 2.29% dividend while Roundhill Russell 2000 0DTE Covered Call Strat ETF pays none, and Merck & Co., Inc. is trading nearer its 52-week high, Roundhill Russell 2000 0DTE Covered Call Strat ETF nearer its low. Which is the better fit depends on your goals.
| MRK | RDTE | |
|---|---|---|
Market Cap | $366.28B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $156.43 | $34.10 |
52-Week Low | $77.60 | $26.40 |
Enterprise Value | $413.04B | — |
Dividend Yield | 2.29% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $148.49, down 1.23% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $156.71. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending, and maintains a robust gross profit margin of 72.97%. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid a competitive pharmaceutical landscape.
The outlook for MRK is positive, driven by earnings momentum and strategic acquisitions, but risks include high valuation multiples like a P/E of 118.77 and regulatory pressures. Investors should weigh the company's solid cash flow and analyst support against potential market volatility and integration challenges from recent M&A activity.
RDTE trades at $27.84, down 0.32% with a bearish technical outlook showing 16 sell signals versus 3 buy signals. The ETF maintains an aggressive dividend distribution strategy with multiple payments in 2026, though key valuation metrics remain unavailable for analysis. Technical indicators show oversold conditions with RSI at 27.52 but strong bearish momentum from moving averages.
The outlook remains cautious due to structural capital erosion risks identified by analysts. While the high dividend yield near 39% attracts income investors, the covered call strategy caps upside potential and exposes investors to full downside risk. Recent analyst reports highlight concerns about NAV deterioration and failure to capture index rallies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Roundhill Russell 2000 0DTE Covered Call Strat ETF
RDTE is an actively managed ETF that seeks to generate income through a covered call strategy on the Russell 2000 Index. The fund primarily holds a portfolio of short-term U.S. government securities and sells 0-DTE (zero days to expiration) index call options on the Russell 2000. This highly tactical strategy aims to maximize premium capture by exploiting the high time decay of options that are expiring on the same day, which provides enhanced income but also exposes the fund to significant volatility and risks associated with daily options settlement.
Read more on RDTE →
